


ETCTN Trials by Disease/Treatment Area: Solid Tumors, No Specified Mutations



NOTE: ▼ Limited trial; not open ETCTN-wide

ETCTN Solid Tumors, No Specified Mutations Trials
(Open as of 1/21/2026)

| Protocol Number | Phase | Protocol Title |
|-----------------|-------|--|
| 10292 | II | DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody MEDI4736 (Durvalumab) in Combination with Chemotherapy in Patients with Advanced Solid Tumors |
| 10204 | Ib | Phase Ib Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO) |
| 10299 | I | A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients |
| 10433 | I/Ib | Phase I/Ib trial evaluating the safety and efficacy of BET inhibitor, ZEN003694 with PD-1 inhibitor, nivolumab with or without CTLA-4 inhibitor, ipilimumab in solid tumors |
| 10486 | II | Phase 2 Trial of the Combination of the BET inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients with Molecularly-Selected Solid Tumors (ComBET) |
| 10499 | Ib/II | Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas |
| 10666 | I | A Dose-Finding Phase I Study of Bone-targeted Stannic-117m Pentatate (Sn-117m-DTPA) in Solid Tumors with Skeletal Metastases |
| 10667 | Pilot | Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors |